Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2020-04-09 Regulatory Filings
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Business Update Related to COVID-19 Pandemic
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange. It provides a business update regarding the COVID-19 pandemic, financial performance, and clinical trial progress. It is not a full financial report (10-K or IR) but rather a corporate update/announcement. Since it does not fit into specific categories like M&A or Dividend announcements, it falls under the general regulatory filing category.
2020-04-09 English
License Agreement with Allogene Therapeutics
Regulatory Filings Classification · 98% confidence The document is a press release issued via the Regulatory News Service (RNS) of the London Stock Exchange. It announces a clinical and commercial license agreement between MaxCyte, Inc. and Allogene Therapeutics. While it involves a business partnership, it does not fit the specific criteria for M&A (which typically involves takeovers or mergers of entities) or other specialized categories. As it is a general regulatory announcement regarding a corporate development, it falls under the RNS category.
2020-03-24 English
Consolidation of Trading Lines
Regulatory Filings Classification · 98% confidence The document is an official announcement from MaxCyte, Inc. regarding the consolidation of two trading lines of its common stock (restricted and unrestricted) into a single unrestricted line. This involves changes to the company's capital structure and share trading symbols. While it is distributed via RNS (Regulatory News Service), the content specifically details a change in share structure and capital organization, which aligns best with the 'Share Issue/Capital Change' category.
2020-02-21 English
AIM Block Admission Return / Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is an 'AIM Block Admission Return' filed via the London Stock Exchange's RNS (Regulatory News Service). It details the issuance of shares under a specific incentive plan and provides an update on the total issued share capital. This type of filing, which reports on changes to share capital and block listing status, falls under the 'Share Issue/Capital Change' category.
2020-02-20 English
MaxCyte to Present at BIO CEO & Investor Conf
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the Regulatory News Service (RNS) announcing that the company's CEO will present at an upcoming investor conference. It provides details about the company's business and technology to generate interest among investors, which is characteristic of an investor-focused announcement or regulatory filing. Since it does not contain a full presentation deck, it is classified as a general regulatory filing (RNS).
2020-02-05 English
Grant Of Options
Director's Dealing Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from MaxCyte, Inc. regarding the 'Grant of Options' to PDMRs (Persons Discharging Managerial Responsibilities). It explicitly details the names of directors and officers, the number of options granted, and includes the mandatory disclosure table required by the EU Market Abuse Regulation (MAR) for director/insider dealings. This falls squarely under the 'Director's Dealing' category.
2020-01-24 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.